Dosimetry of intraperitoneally administered radiolabeled antibodies

Medical Physics

Volumn 20, Issue 2, 1993, Pages 593-600

  Roeske, John C ^a   Brill, A Bertrand ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

alpha and beta emitters; dosimetry; intraperitoneal radioimmunotherapy; models

Indexed keywords

ANTIBODY; IODINE 131; RADIOISOTOPE; YTTRIUM 90;

ALPHA RADIATION; ANTIBODY LABELING; ARTICLE; BETA RADIATION; CANCER IMMUNOTHERAPY; DOSE CALCULATION; DOSIMETRY; DRUG DISTRIBUTION; DRUG PENETRATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; RADIOBIOLOGY; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; HUMAN; INFUSIONS, PARENTERAL; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027262316     PISSN: 00942405     EISSN: NA     Source Type: Journal    
DOI: 10.1118/1.597054     Document Type: Article

References (51)

1. J. Malamitsi, D. Skarlos, S. Fotiou, P. Papakostas, G. Aravantinos, D. Vassilarou, J. Taylor-Papadimitriou, K. Koutoulidis, G. Hooker, D. Snook, and A. Epenetos, “Intracavity use of two tumor associated monoclonal antibodies,”; J. Nucl. Med. 29, 1910–1915 (1988).
2. G. Rowlinson, D. Snook, A. Busza, and A. Epenetos, “Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous administration,”; Cancer Res. 47, 6528–6531 (1987).
3. N. J. Finkler, M. G. Muto, A. I. Kassis, K. Weadock, S. S. Tumeh, V. R. Zurawski, and R. C. Knapp, “Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer,”; Gynecol. Oncol. 34, 339–344 (1989).
4. J. F. Chatal, J. C. Saccavini, J. F. Gestin, P. Thedrez, C. Curtet, M. Kremer, D. Gurreau, D. Nolibe, P. Fumoleau, and Y. Guillard, “Bio-distribution of indium-111 labeled monoclonal antibody after intraperitoneal injection in nude mice intraperitoneally grafted with ovarian carcinoma,”; Cancer Res. 49, 3081–3086 (1989).
5. A. A. Epenetos, G. Hooker, T. Krausz, D. Snook, W. Bodmer, and J. Taylor-Papadimitriou, “Antibody-guided irradiation of malignant ascites in ovarian cancer: A new therapeutic method possessing specificity against cancer cells,”; Obst. Gynecol, (supplement) 68, 71S-74S (1986).
6. H. Haisma, K. Moseley, A. Battaile, T. C. Griffiths, and R. C. Knapp, “Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors,”; Am. J. Obstet. Gyncol. 159, 4218–4224 (1987).
7. D. Colcher, J. Esteban, J. A. Carrasquillo, P. Sugarbaker, J. C. Reynolds, G. Bryant, S. M. Larson, and J. Schlom, “Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma,”; Cancer Res. 47, 4218–4224 (1987).
8. J. S. Stewart, V. Hird, D. Snook, M. Sullivan, G. F. Hooker, N. Courtenay-Luck, G. Sivolapenko, M. Griffiths, M. J. Myers, H. E. Lambert, A. J. Munro, and A. A. Epenetos, “Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of 1–131 labeled monoclonal antibodies,”; Int. J. Radiat. Oncol. Biol. Phys. 16, 405–413 (1989).
9. A. A. Epenetos, A. J. Munro, S. Stewart, R. Rampling, H. E. Lambert, C. G. McKenzie, P. Soutter, A. Rahemtulla, G. Hooker, G. B. Sivol-apenko, D. Snook, N. Courtenay-Luck, B. Dhokia, T. Krausz, J. Taylor-Papadimitriou, H. Durbin, and W. F. Bodmer, “Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies,”; J. Clin. Oncol. 5, 1890–1899 (1987).
10. D. J. Hnatowich, M. Chinol, D. A. Siebecker, M. Gionet, P. W. Doherty, R. Hunter, and K. Kase, “Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody,”; J. Nucl. Med. 29, 1428–1434 (1988).
11. J. Stewart, V. Hird, D. Snook, M. Sullivan, M. J. Myers, and A. A. Epenetos, “Intraperitoneal 1–131 and Y-90 labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry,”; Int. J. Radiat. Oncol. Biol. Phys. 16, 405–413 (1989).
12. B. G. Ward, S. J. Mather, J. H. Shepherd, K. E. Britton, M. Gra-nowska, and, ‘Response to prospects for antibody-targeted radiotherapy of cancer,”; Lancet 2, 580–581 (1986).
13. D. Colcher, J. Esteban, J. A. Carrasquillo, P. Sugarbaker, J. C. Reynolds, G. Bryant, S. M. Larson, and J. Schlom, ‘Comparison of route of administration of radiolabeled monoclonal antibodies in patients with colorectal cancer,”; J. Nucl. Med. 27 (6), 902 (1986).
14. P. Riva, S. Lazzari, M. Agostini, G. Sarti, G. Mosentelli, A. Pagenelli, L. Rasciti, and A. Siccardi, ‘The intraperitoneal administration of ra-diolabelled monoclonal antibodies for the diagnosis and therapy of colon cancer,”; J. Nucl. Med. 29 (5), 762 (1988) (Abstract).
15. L. S. Lashford, A. G. Davies, R. B. Richardson, S. P. Bourne, J. A. Bullimore, H. Eckert, J. T. Kemstead, and H. B. Coakham, ‘A pilot study of 1–131 monoclonal antibodies in the therapy of leptomeningeal tumours,”; Cancer 58, 573–583 (1986).
16. W. T. Miller and A. Barrett, Dosimetric model for antibody targeted radionuclide therapy and tumor cells in cerebrospinal fluid,”; Cancer Res. (Supplement) 50, 1043S-1048S (1990).
17. D. Pectasides, S. Stewart, N. Courtenay-Luck, R. Rampling, A. J. Munro, T. Krausz, B. Dhokia, D. Snook, G. Hooker, H. Durbin, J. Taylor-Papadimitriou, W. F. Bodmer, and A. A. Epenetos, “Antibody-guided irradiation of malignant pleural and pericardial effusions,”; Br. J. Cancer 5, 727–732 (1986).
18. N. Courtenay-Luck, A. A. Epenetos, K. E. Halnan G. Hooker, J. M. B. Hughes, T. Krausz, J. Lambert, J. P. Lavender, W. G. MacGregor, C. J. McKenzie, A. Munro, M. J. Myers, J. S. Orr, E. E. Pearse, D. Snook, B. Webb, J. Burchell, H. Durbin, J. Kemstead, and J. Taylor-Papadimitriou, “Antibody-guided irradiation of malignant lesions: Three cases illustrating a new method of treatment,”; The Lancet 1, 1441–1443 (1984).
19. P. Riva, A. Arista, G. Mariani, E. Seccamani, S. Lazzari, G. Mosca-telli, C. Sturiale, G. Sarti, G. Franceschi, A. Spinelli, G. Vecchietti, N. Riva, P. Natali, and L. Zardi, “Improved tumour targeting by direct intralesional injection of radiolabeled monoclonal antibody: A phase I study in brain glioma,”; J. Nucl. Med. 32, 922 (1991).
20. R. F. Ozols and R. C. Young, “Ovarian cancer,”; Cur. Prob. Cancer 11, 37–122 (1987).
21. Z. Fuks, J. Yahalom, and H. Brenner, The Treatment of Carcinoma of the Ovary in a Radiation Therapy of Gynecologic Cancers (Alan R. Liss, New York, 1987).
22. J. Horyon and T. Caputo, Gynecologic Cancer in Clinical Oncology (W. B. Saunders, New York, 1977).
23. G. A. Andrews, S. Root, H. D. Kerman, and R. R. Bigelow, “Intrac-avitary colloidal radiogold in the treatment of effusion caused by malignant neoplasm,”; Ann. Surg. 137, 375–381 (1953).
24. E. Boye, M. W. Lindegoard, E. Paus, A. Skretting, M. Davy, and E. Jacobsen, “Whole-body distribution of radioactivity after intraperitoneal administration of P-32 colloids,”; Br. J. Radiol. 57, 395–402 (1984).
25. J. L. Currie, F. Bagne, C. Harris, D. L. Sullivan, E. A. Suruit, R. H. Wilkinson, and W. T. Creasman, “Radioactive chromic phosphate suspension: Studies on distribution, dose absorption and effective therapeutic radiation in phantoms, dogs and patients,”; Gynecol. Oncol. 12, 193–218 (1981).
26. R. J. Ott, M. A. Flower, A. Jones, and V. R. McCready, “The application of SPET to determine the radiation dose from P-32-chromic phosphate therapy of the peritoneal cavity,”; Euro. J. Nucl. Med. 11, 305–308 (1985).
27. B. Rippe and G. Stelin, “Simulations of peritoneal solute transport during CAPD. Application of the two-pore formalism,”; Kidney Int. 35, 1234–1244 (1989).
28. M. F. Flessner, R. L. Dedrick, and J. S. Schultz, “Exchange of macromolecules between peritoneal cavity and plasma,”; Am. J. Physiol. 248, H15-H25 (1985).
29. M. F. Flessner, J. D. Fenstermacher, R. G. Blasberg, and R. L. De-drick, “Peritoneal absorption of macromolecules studied by quantitative autoradiography,”; Am. J. Physiol. 248, H26-H32 (1985).
30. J. F. Chatal, J. C. Saccavini, J. F. Gestin, P. Thedrez, C. Curtet, M. Kremer, D. Guerreau, D. Nobile, P. Fumoleau, and Y. Guillard, “Bio-distribution of indium-lll-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas,”; Cancer Res. 49, 3087–3094 (1989).
31. P. Thedrez J. C. Saccavini, D. Nolibe, J. P. Simoen, D. Guerreau, J. F. Gestin C. Curtet, M. Kremer, and J. F. Chatal, “Biodistribution of indium-111-labeled OC 125 monoclonal antibody after intraperitoneal injection in nude mice intraperitoneally grafted with ovarian carcinomas,”; Cancer Res. 49, 3081–3086 (1989).
32. J. Rotmensch, J. Roeske, G. Chen, C. Pelizzati, A. Montag, R. Weichselbaum, and A. L. Herbst, “Estimates of dose to intraperitoneal micrometastases from alpha and beta emitter in radioimmunotherapy,”; Gynecol. Oncol. 38, 478-485 (1990).
33. L. M. Cobb, “Intratumor factors influencing the access of antibody to tumour cells,”; Cancer Immunol. Immunother. 28, 235–240 (1989).
34. R. K. Jain, “Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors,”; Cancer Res. (Supplement) 50, 814S-819S (1990).
35. R. L. Dedrick and M. F. Flessner, “Pharmacokinetic considerations on monoclonal antibodies,”; Immunity Cancer 2, 429–438 (1989).
36. C. A. Sutherland, J. O. Davis, G. M. Stirrat, F. Buchegger, M. Schreyer, A. Vacca, and J. P. Mach, “Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular spheroids,”; Cancer Res. 47, 1627–1633 (1987).
37. G. D. Thomas, M. J. Chappell, P. W. Dykes, D. B. Ramsden, K. R. Godfrey, J. R. M. Ellis, and A. R. Bradwell, “Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: A biomathematical model,”; Cancer. Res. 49, 3290–3296 (1989).
38. L. E. Williams, R. B. Duda, R. T. Proffitt, B. G. Beatty, J. D. Beatty, J. Y. C. Wong, J. E. Shively, and R. Paxton, “Tumor uptake as a model of tumor mass: A mathematical model,”; J. Nucl. Med. 29, 103–109 (1988).
39. K. Fujimori, D. G. Coveil, J. E. Fletcher, and J. N. Weinstein, “Modeling analysis of the global and microscopic distribution of Immunoglobulin G, F(ab‘)2 and Fab in tumors,”; Cancer Res. 49, 5656–5663 (1989).
40. K. Fujimori, D. G. Covell, J. E. Fletcher, and J. N. Weinstein, “A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier,”; J. Nucl. Med. 31, 1191–1198 (1990).
41. K. Fujimori, D. Fisher, and J. N. Weinstein, “Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioimmunoconjugates: The radiation dose distribution,”; Cancer Res. 51, 4821–4827 (1991).
42. L. T. Baxter and R. K. Jain, “Transport of fluid molecules in tumors: I. Role of interstitial pressure and convection,”; Microvasc. Res. 48, 77–109 (1989).
43. M. J. Myers, A. A. Epenetos, and G. Hooker, “Practical assessment of radiation doses using labelled antibodies for therapy,”; Nucl. Med. Biol. 13(4), 437–446 (1986).
44. M. J. Myers, G. R. Hooker, and A. A. Epenetos, “Dosimetry of radiolabeled monoclonal antibodies used for therapy,”; in Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium (Oak Ridge, TN, Conf-851113, 1985).
45. M. Bardies, J. Lame, M. J. Myers, and J. P. Simoen, “A simplified approach to beta dosimetry for small spheres labelled on the surface,”; Phys. Med. Biol. 35, 1039–1050 (1990).
46. M. Bardies and M. J. Myers, “A simplified approach to alpha dosimetry for small spheres labelled on the surface,”; Phys. Med. Biol. 35(11), 1551–1561 (1990).
47. E. E. Watson, M. G. Stabin, J. L. Davis and K. F. Eckerman, “A model of the peritoneal cavity for use in internal dosimetry,”; J. Nucl. Med. 30, 2002–2011 (1989).
48. J. C. Roeske, G. T. Y. Chen, R. W. Atcher, C. A. Pelizzari, J. Rot-mensch, D. Haraf, A. Montag, and R. R. Weichselbaum, “Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters,”; Int. J. Radiat. Oncol. Biol. Phys. 19(6), 1539–1548 (1990).
49. R. Loevinger, E. Japha, and G. Brownell, Radiation Dosimetry (Aca-demic, New York, 1958).
50. M. Berger, “Distribution of absorbed dose around point sources of electrons and beta particles in water and other media,”; MIRD Pamphlet No. 7, J. Nucl. Med. (Supplement 5) (1971).
51. M. H. Griffith, E. D. Yorke, B. W. Wessels, G. L. DeNardo, and W. P. Neacy, “Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy,”; J. Nucl. Med. 29, 1795–1809 (1988).